Protective Efficacy of Subunit Vaccine Expressing Rv0976c Against Tuberculosis
These results indicated that Rv0976c was a better protective antigen. Future studies to combine Rv0976c with other antigens and evaluate its effectiveness as a booster of BCG or as a therapeutic vaccine are warranted.
Authors
- Zhi-hao Xiang
- Fagang Zhong
- Wenxi Xu (ORCID: https://orcid.org/0000-0001-6969-4408)
- Lu Zhang (ORCID: https://orcid.org/0000-0002-4858-0361)
- Fu-zeng Chen
- Yeyu Li
- Jun Liu (ORCID: https://orcid.org/0000-0002-0522-6733)
- Zhifen Pan (ORCID: https://orcid.org/0000-0002-1692-5425)
- Ziwei Zhou
- Xiaoxiao Gao (ORCID: https://orcid.org/0000-0003-3017-9171)
- Dan Chen (ORCID: https://orcid.org/0009-0007-2001-3334)
Institutions
- University of Toronto (CA)
- Fudan University (CN)
- Princess Margaret Cancer Centre (CA)
- Shanghai Micro Satellite Engineering Center (CN)
- Xinjiang Academy of Agricultural and Reclamation Science (CN)
- First Hospital of Jiaxing (CN)
- State Key Laboratory of Genetic Engineering
Publication Details
- Journal
- Vaccines
- Published
- 2025-08-17
- DOI
- https://doi.org/10.3390/vaccines13080872
- Primary Topic
- Tuberculosis Research and Epidemiology
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Xinjiang Production and Construction Corps
- National Key Research and Development Program of China